Author:
Kulasekararaj Austin,Brodsky Robert,Kulagin Alexander,Jang Jun Ho
Abstract
Biologics, a class of medicines grown in and purified from genetically engineered cell cultures, have transformed the management of many cancers and rare diseases, such as paroxysmal nocturnal hemoglobinuria. As prescription drug spending has increased and exclusivity periods have expired, manufacturers have developed biosimilars–biologics that may be more affordable and highly similar to a licensed biological therapeutic, with no clinically meaningful differences in terms of safety or efficacy. With biosimilars gaining regulatory approval around the globe and broadening patient access to biologics, this review aims to help rare disease healthcare providers familiarize themselves with biosimilars, understand their development and regulatory approval process, and address practical considerations that may facilitate their use.
Publisher
Ferrata Storti Foundation (Haematologica)
Reference71 articles.
1. Crosson FJ. Addressing the cost of biologic and specialty drugs. JAMA Intern Med. 2021; 181(1):22-23.
2. European Medicines Agency. Biosimilars in the EU - Information guide for healthcare professionals. Updated 02/10/2019. 2021.
3. European Medicines Agency. Omnitrope. European public assessment report (EPAR) summary for the public. Updated 28/04/2021. 2021.
4. Kang HN, Thorpe R, Knezevic I. noindent1Survey participants from 19 countries. The regulatory landscape of biosimilars: WHO efforts and progress made from 2009 to 2019. Biologicals. 2020; 65:1-9.
5. US Food and Drug Administration. Biosimilars action plan: balancing innovation and competition. 2018.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献